Martin LenÃ-Äek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/594546/publications.pdf

Version: 2024-02-01

471509 434195 1,112 51 17 31 citations h-index g-index papers 51 51 51 1992 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. American Journal of Physiology - Renal Physiology, 2010, 298, G440-G445.	3.4	132
2	Bile acid malabsorption in inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1322-1327.	1.9	102
3	Differences in antitumor effects of various statins on human pancreatic cancer. International Journal of Cancer, 2008, 122, 1214-1221.	5.1	93
4	Highly sensitive method for quantitative determination of bilirubin in biological fluids and tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 867, 37-42.	2.3	67
5	The Relationship Between Serum Bilirubin and Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 481-487.	1.9	44
6	Bile acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress. Journal of Cellular and Molecular Medicine, 2011, 15, 1156-1165.	3.6	39
7	Determination of Beta-Defensin Genomic Copy Number in Different Populations: A Comparison of Three Methods. PLoS ONE, 2011, 6, e16768.	2.5	39
8	Cholic acid therapy in Zellweger spectrum disorders. Journal of Inherited Metabolic Disease, 2016, 39, 859-868.	3.6	37
9	Use of Non-Invasive Parameters of Non-Alcoholic Steatohepatitis and Liver Fibrosis in Daily Practice - An Exploratory Case-Control Study. PLoS ONE, 2014, 9, e111551.	2.5	37
10	Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry Research, 2010, 178, 449-450.	3.3	31
11	Cholestatic effect of epigallocatechin gallate in rats is mediated via decreased expression of Mrp2. Toxicology, 2013, 303, 9-15.	4.2	27
12	Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World Journal of Gastroenterology, 2016, 22, 3441-3450.	3.3	25
13	Microbiome and Metabolome Profiles Associated With Different Types of Short Bowel Syndrome: Implications for Treatment. Journal of Parenteral and Enteral Nutrition, 2020, 44, 105-118.	2.6	24
14	Protective effect of heme oxygenase induction in ethinylestradiolâ€induced cholestasis. Journal of Cellular and Molecular Medicine, 2015, 19, 924-933.	3.6	23
15	Effect of Omegaâ€3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatology Communications, 2022, 6, 1336-1349.	4.3	22
16	Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Research and Therapy, 2015, 17, 371.	3.5	20
17	Iron depletion induces hepatic secretion of biliary lipids and glutathione in rats. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 1469-1480.	2.4	19
18	The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy. Journal of Inherited Metabolic Disease, 2019, 42, 303-312.	3.6	18

#	Article	IF	Citations
19	Comparison of simple extraction procedures in liquid chromatographyâ¿mass spectrometry based determination of serum 7î±-hydroxy-4-cholesten-3-one, a surrogate marker of bile acid synthesis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1033-1034, 317-320.	2.3	17
20	NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. World Journal of Gastroenterology, 2010, 16, 5233.	3.3	17
21	Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. Scandinavian Journal of Gastroenterology, 2006, 41, 1454-1463.	1.5	16
22	Improved HPLC Analysis of Serum 7î±-Hydroxycholest-4-en-3-one, a Marker of Bile Acid Malabsorption. Clinical Chemistry, 2008, 54, 1087-1088.	3.2	16
23	The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's disease. BMC Medical Genetics, 2010, 11, 91.	2.1	16
24	Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge. Hepatology International, 2017, 11, 132-140.	4.2	16
25	CYP7A1 promoter polymorphism â^203A>C affects bile salt synthesis rate in patients after ileal resection. Journal of Lipid Research, 2008, 49, 2664-2667.	4.2	15
26	Association of <i>IL23R</i> p.381Gln and <i>ATG16L1</i> p.197Ala With Crohn Disease in the Czech Population. Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 405-410.	1.8	12
27	Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. European Journal of Gastroenterology and Hepatology, 2010, 22, 1196-1203.	1.6	12
28	Expression of Biliverdin Reductase A in Peripheral Blood Leukocytes Is Associated with Treatment Response in HCV-Infected Patients. PLoS ONE, 2013, 8, e57555.	2.5	12
29	Parenteral nutrition dysregulates bile salt homeostasis in a rat model of parenteral nutrition-associated liver disease. Clinical Nutrition, 2017, 36, 1403-1410.	5.0	12
30	Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a Model for End-Stage Intestinal Failure (MESIF risk score). American Journal of Clinical Nutrition, 2019, 109, 1620-1629.	4.7	12
31	Cytoprotective and Antiproliferative Effects of HMG-CoA Reductase Inhibitors. Current Enzyme Inhibition, 2006, 2, 261-280.	0.4	11
32	Simultaneous genotyping of microsatellite variations in HMOX1 and UGT1A1 genes using multicolored capillary electrophoresis. Clinical Biochemistry, 2010, 43, 697-699.	1.9	11
33	No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C. Annals of Hepatology, 2011, 10, 445-451.	1.5	11
34	Hyperbilirubinemia in Gunn Rats Is Associated with Decreased Inflammatory Response in LPS-Mediated Systemic Inflammation. International Journal of Molecular Sciences, 2019, 20, 2306.	4.1	10
35	A novel accurate LC-MS/MS method for quantitative determination of Z-lumirubin. Scientific Reports, 2020, 10, 4411.	3.3	10
36	Antiâ€angiogenic effects of the blueâ€green alga Arthrospira platensis on pancreatic cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 2402-2415.	3.6	10

#	Article	IF	CITATIONS
37	Two independent genetic factors responsible for the associations of the IBD5 locus with Crohn's disease in the Czech population. Inflammatory Bowel Diseases, 2011, 17, 1523-1529.	1.9	9
38	Serum Bilirubin Concentrations and the Prevalence of Gilbert Syndrome in Elite Athletes. Sports Medicine - Open, 2022, 8 , .	3.1	9
39	Chyme Reinfusion Restores the Regulatory Bile Salt–FGF19 Axis in Patients With Intestinal Failure. Hepatology, 2021, 74, 2670-2683.	7.3	8
40	Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically III Patients. Hepatology, 2019, 70, 308-318.	7.3	7
41	No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C. Annals of Hepatology, 2011, 10, 445-51.	1.5	7
42	New Kids on the Block: Bile Salt Conjugates of Microbial Origin. Metabolites, 2022, 12, 176.	2.9	7
43	The clinical implication of drug dependency in children and adults with inflammatory bowel disease: A review. Journal of Crohn's and Colitis, 2011, 5, 81-90.	1.3	6
44	Diurnal variation in cholesterol 7î±-hydroxylase activity is determined by the -203A>C polymorphism of the CYP7A1 gene. Croatian Medical Journal, 2016, 57, 111-117.	0.7	6
45	Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants, 2021, 10, 2000.	5.1	6
46	Enzymatic methods may underestimate the total serum bile acid concentration. PLoS ONE, 2020, 15, e0236372.	2.5	5
47	Gut Microbes Take It to the Next Level? First Insights Into Farnesoid X Receptor Agonists of Microbial Origin. Hepatology, 2020, 72, 1483-1485.	7.3	3
48	Functional variants of <i>eNOS </i> and <i>iNOS </i> genes have no relationship to the portal hypertension in patients with liver cirrhosis. Scandinavian Journal of Gastroenterology, 2013, 48, 592-601.	1.5	2
49	The cholic acid extension study in Zellweger spectrum disorders: results and implications for therapy. Journal of Inherited Metabolic Disease, 2018, , .	3.6	2
50	Mathematical recalibration of total bile acids: comparing the incomparable?. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1889-1890.	2.3	0
51	Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant. Scientific Reports, 2021, 11, 20924.	3.3	0